NICE backs Eylea for macular edema

The U.K.'s NICE issued a Eylea aflibercept from Bayer AG (Xetra:BAYN) to treat visual impairment caused by macular edema secondary to central retinal vein occlusion (CRVO). The recommendation is contingent on Bayer providing Eylea at an undisclosed discount under a patient access scheme. The committee did not issue draft guidance because the recommendation is in line with an approved EU indication for Eylea; the European Commission approved Eylea to treat visual impairment due to macular edema secondary to CRVO in August. Final guidance is expected in February.

Eylea is also approved in Europe to treat wet age-related macular degeneration (AMD); NICE already backs Eylea for that indication. The human fusion protein that binds all forms of VEGF-A and placental growth factor ( PGF; PlGF) is approved in the U.S. for wet AMD and macular edema following CRVO, and is approved for wet AMD in Japan, Australia, Switzerland and some Latin American countries. ...